scPharmaceuticals Inc
NASDAQ:SCPH
scPharmaceuticals Inc
NASDAQ:SCPH
Price:
5.67
USD
Market Closed
Market Cap:
$304.4m
Balance Sheet
Balance Sheet Decomposition
scPharmaceuticals Inc
scPharmaceuticals Inc
Balance Sheet Decomposition is not available for
scPharmaceuticals Inc
scPharmaceuticals Inc
Balance Sheet
scPharmaceuticals Inc
scPharmaceuticals Inc
Currency: USD
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
2
|
39
|
118
|
90
|
73
|
72
|
74
|
71
|
47
|
76
|
|
| Cash Equivalents |
2
|
39
|
118
|
90
|
73
|
72
|
74
|
71
|
47
|
76
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
33
|
1
|
47
|
29
|
0
|
|
| Total Receivables |
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
4
|
12
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
12
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
9
|
14
|
|
| Other Current Assets |
0
|
0
|
1
|
2
|
3
|
3
|
3
|
4
|
4
|
5
|
|
| Total Current Assets |
2
|
40
|
120
|
92
|
76
|
108
|
78
|
123
|
93
|
106
|
|
| PP&E Net |
0
|
0
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| PP&E Gross |
0
|
0
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
2
N/A
|
40
+2 111%
|
122
+207%
|
94
-23%
|
77
-18%
|
109
+41%
|
79
-28%
|
124
+57%
|
94
-24%
|
108
+14%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1
|
2
|
2
|
1
|
1
|
2
|
1
|
2
|
4
|
4
|
|
| Accrued Liabilities |
1
|
2
|
3
|
3
|
4
|
5
|
5
|
6
|
9
|
11
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
3
|
0
|
2
|
10
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
2
|
4
|
5
|
7
|
5
|
9
|
15
|
7
|
13
|
15
|
|
| Long-Term Debt |
0
|
0
|
9
|
7
|
19
|
17
|
7
|
37
|
39
|
51
|
|
| Other Liabilities |
0
|
0
|
2
|
2
|
2
|
1
|
0
|
8
|
5
|
28
|
|
| Total Liabilities |
2
N/A
|
4
+85%
|
16
+335%
|
15
-7%
|
26
+73%
|
27
+4%
|
23
-16%
|
52
+129%
|
57
+11%
|
94
+65%
|
|
| Equity | |||||||||||
| Common Stock |
18
|
73
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
19
|
43
|
67
|
97
|
130
|
162
|
190
|
227
|
281
|
366
|
|
| Additional Paid In Capital |
1
|
6
|
173
|
175
|
181
|
244
|
246
|
299
|
319
|
380
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
0
N/A
|
36
N/A
|
106
+194%
|
79
-26%
|
51
-35%
|
82
+60%
|
57
-31%
|
72
+28%
|
37
-49%
|
13
-64%
|
|
| Total Liabilities & Equity |
2
N/A
|
40
+2 111%
|
122
+207%
|
94
-23%
|
77
-18%
|
109
+41%
|
79
-28%
|
124
+57%
|
94
-24%
|
108
+14%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
18
|
8
|
19
|
19
|
19
|
27
|
27
|
34
|
36
|
50
|
|
Switch to:
Switch to:
See Also
Discover More
